Borderline Resectable Adrenal Cortical Carcinoma: A Potential Role for Preoperative Chemotherapy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-03-11

AUTHORS

Brian K. Bednarski, Mouhammed Amir Habra, Alexandria Phan, Denai R. Milton, Christopher Wood, Nicholas Vauthey, Douglas B. Evans, Matthew H. Katz, Chaan S. Ng, Nancy D. Perrier, Jeffrey E. Lee, Elizabeth G. Grubbs

ABSTRACT

BackgroundAdrenal cortical carcinoma (ACC) may have tumor or patient characteristics at presentation that argue against immediate surgery because of an unacceptable risk of morbidity/mortality, incomplete resection, or recurrence. This clinical stage can be characterized as borderline resectable ACC (BRACC). At present, systemic therapies in ACC can reduce tumor burden in some patients, creating an opportunity in BRACC for a strategy of preoperative chemotherapy (ctx) followed by surgery.Materials and MethodsA single-institution retrospective review was conducted of all patients considered for surgery for primary ACC. Patients with BRACC treated with preoperative ctx were categorized as follows: group A, imaging suggesting a need for multiorgan/vascular resection; group B, imaging suggesting potentially resectable oligometastases; and group C, patients having marginal performance status/comorbidities precluding immediate surgery. Both the disease-free survival (DFS) and the overall survival (OS) were compared in BRACC patients treated with preoperative ctx+surgery and those who had upfront surgery.ResultsFifty-three patients with primary ACC were considered for surgery (median follow-up: 49.9 months). Thirty-eight patients (71.7 %) had initial surgery and 15 of them (28.3 %) were considered BRACC and received preoperative therapy. Of these 15 patients, 12 (80 %) received combination therapy with mitotane and etoposide/cisplatin-based ctx, 2 (13 %) received mitotane alone, and 1 (7 %) received ctx alone. Six patients were defined as group A, 5 as group B, and 4 as group C. Thirteen (87 %) BRACC patients underwent surgical resection. BRACC patients were younger but had more advanced disease than the patients having initial surgery (stage IV in 40 vs 2.6 % [p < 0.01]). By Response Evaluation Criteria In Solid Tumors criteria, 5 patients (38.5 %) had a partial response, 7 (53.8 %) had stable disease, and 1 (7.7 %) had disease that progressed. Postoperative mitotane use was similar between groups (p = .15). Median DFS for resected BRACC patients was 28.0 months [95 % confidence interval (CI), 2.9–not attained] vs 13 months (95 % CI, 5.8–46.9) (p = 0.40) for initial surgery patients. Five-year OS rates were also similar: 65 % for resected BRACC vs 50 % for initial surgery (p = 0.72).ConclusionsThe favorable outcome of patients with BRACC, despite more advanced stage of disease compared to those treated with surgery first, together with uncommon disease progression, suggests a benefit of neoadjuvant treatment sequencing in patients with BRACC. More... »

PAGES

1318-1327

Journal

TITLE

World Journal of Surgery

ISSUE

6

VOLUME

38

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00268-014-2484-4

DOI

http://dx.doi.org/10.1007/s00268-014-2484-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052270792

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24615603


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenal Cortex Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenalectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenocortical Carcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biopsy, Needle", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Confidence Intervals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunohistochemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Invasiveness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Preoperative Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Role", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Statistics, Nonparametric", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tomography, X-Ray Computed", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bednarski", 
        "givenName": "Brian K.", 
        "id": "sg:person.0641505371.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641505371.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Habra", 
        "givenName": "Mouhammed Amir", 
        "id": "sg:person.014015460707.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014015460707.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Methodist Cancer Center, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Medical Oncology, Methodist Cancer Center, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Phan", 
        "givenName": "Alexandria", 
        "id": "sg:person.07703274637.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07703274637.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biostatistics, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Biostatistics, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Milton", 
        "givenName": "Denai R.", 
        "id": "sg:person.01331214305.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331214305.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wood", 
        "givenName": "Christopher", 
        "id": "sg:person.01040121722.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vauthey", 
        "givenName": "Nicholas", 
        "id": "sg:person.01123234424.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123234424.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Medical College of Wisconsin, 53226, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Department of Surgery, Medical College of Wisconsin, 53226, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Evans", 
        "givenName": "Douglas B.", 
        "id": "sg:person.011430047362.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011430047362.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Katz", 
        "givenName": "Matthew H.", 
        "id": "sg:person.010520141322.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010520141322.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Radiology, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ng", 
        "givenName": "Chaan S.", 
        "id": "sg:person.010313117317.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010313117317.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Perrier", 
        "givenName": "Nancy D.", 
        "id": "sg:person.0630717166.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630717166.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Jeffrey E.", 
        "id": "sg:person.015020157564.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015020157564.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grubbs", 
        "givenName": "Elizabeth G.", 
        "id": "sg:person.01331416616.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331416616.43"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1245/s10434-009-0416-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036571674", 
          "https://doi.org/10.1245/s10434-009-0416-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-009-0716-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009990166", 
          "https://doi.org/10.1245/s10434-009-0716-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-009-0409-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033782523", 
          "https://doi.org/10.1245/s10434-009-0409-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-009-0413-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018660030", 
          "https://doi.org/10.1245/s10434-009-0413-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-012-2358-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029414516", 
          "https://doi.org/10.1245/s10434-012-2358-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-03-11", 
    "datePublishedReg": "2014-03-11", 
    "description": "BackgroundAdrenal cortical carcinoma (ACC) may have tumor or patient characteristics at presentation that argue against immediate surgery because of an unacceptable risk of morbidity/mortality, incomplete resection, or recurrence. This clinical stage can be characterized as borderline resectable ACC (BRACC). At present, systemic therapies in ACC can reduce tumor burden in some patients, creating an opportunity in BRACC for a strategy of preoperative chemotherapy (ctx) followed by surgery.Materials and MethodsA single-institution retrospective review was conducted of all patients considered for surgery for primary ACC. Patients with BRACC treated with preoperative ctx were categorized as follows: group A, imaging suggesting a need for multiorgan/vascular resection; group B, imaging suggesting potentially resectable oligometastases; and group C, patients having marginal performance status/comorbidities precluding immediate surgery. Both the disease-free survival (DFS) and the overall survival (OS) were compared in BRACC patients treated with preoperative ctx+surgery and those who had upfront surgery.ResultsFifty-three patients with primary ACC were considered for surgery (median follow-up: 49.9\u00a0months). Thirty-eight patients (71.7\u00a0%) had initial surgery and 15 of them (28.3\u00a0%) were considered BRACC and received preoperative therapy. Of these 15 patients, 12 (80\u00a0%) received combination therapy with mitotane and etoposide/cisplatin-based ctx, 2 (13\u00a0%) received mitotane alone, and 1 (7\u00a0%) received ctx alone. Six patients were defined as group A, 5 as group B, and 4 as group C. Thirteen (87\u00a0%) BRACC patients underwent surgical resection. BRACC patients were younger but had more advanced disease than the patients having initial surgery (stage IV in 40 vs 2.6\u00a0% [p\u00a0<\u00a00.01]). By Response Evaluation Criteria In Solid Tumors criteria, 5 patients (38.5\u00a0%) had a partial response, 7 (53.8\u00a0%) had stable disease, and 1 (7.7\u00a0%) had disease that progressed. Postoperative mitotane use was similar between groups (p\u00a0=\u00a0.15). Median DFS for resected BRACC patients was 28.0\u00a0months [95\u00a0% confidence interval (CI), 2.9\u2013not attained] vs 13\u00a0months (95\u00a0% CI, 5.8\u201346.9) (p\u00a0=\u00a00.40) for initial surgery patients. Five-year OS rates were also similar: 65\u00a0% for resected BRACC vs 50\u00a0% for initial surgery (p\u00a0=\u00a00.72).ConclusionsThe favorable outcome of patients with BRACC, despite more advanced stage of disease compared to those treated with surgery first, together with uncommon disease progression, suggests a benefit of neoadjuvant treatment sequencing in patients with BRACC.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00268-014-2484-4", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438826", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1086446", 
        "issn": [
          "0364-2313", 
          "1432-2323"
        ], 
        "name": "World Journal of Surgery", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "38"
      }
    ], 
    "keywords": [
      "disease-free survival", 
      "initial surgery", 
      "preoperative chemotherapy", 
      "immediate surgery", 
      "overall survival", 
      "primary ACC", 
      "group B", 
      "group A", 
      "median disease-free survival", 
      "Five-year OS rates", 
      "single-institution retrospective review", 
      "neoadjuvant treatment sequencing", 
      "Solid Tumors criteria", 
      "Response Evaluation Criteria", 
      "ResultsFifty-three patients", 
      "morbidity/mortality", 
      "preoperative CTx", 
      "upfront surgery", 
      "Tumors criteria", 
      "stable disease", 
      "cortical carcinoma", 
      "vascular resection", 
      "preoperative therapy", 
      "advanced disease", 
      "patient characteristics", 
      "incomplete resection", 
      "systemic therapy", 
      "surgical resection", 
      "partial response", 
      "surgery patients", 
      "retrospective review", 
      "OS rates", 
      "tumor burden", 
      "clinical stage", 
      "combination therapy", 
      "treatment sequencing", 
      "favorable outcome", 
      "disease progression", 
      "surgery", 
      "patients", 
      "group C", 
      "advanced stage", 
      "resection", 
      "disease", 
      "therapy", 
      "CTX", 
      "potential role", 
      "chemotherapy", 
      "mitotane", 
      "months", 
      "survival", 
      "unacceptable risk", 
      "oligometastases", 
      "comorbidities", 
      "carcinoma", 
      "recurrence", 
      "ACC", 
      "tumors", 
      "mortality", 
      "progression", 
      "outcomes", 
      "burden", 
      "risk", 
      "criteria", 
      "presentation", 
      "review", 
      "evaluation criteria", 
      "group", 
      "stage", 
      "response", 
      "sequencing", 
      "role", 
      "benefits", 
      "rate", 
      "need", 
      "use", 
      "strategies", 
      "characteristics", 
      "opportunities", 
      "materials"
    ], 
    "name": "Borderline Resectable Adrenal Cortical Carcinoma: A Potential Role for Preoperative Chemotherapy", 
    "pagination": "1318-1327", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052270792"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00268-014-2484-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24615603"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00268-014-2484-4", 
      "https://app.dimensions.ai/details/publication/pub.1052270792"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_620.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00268-014-2484-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00268-014-2484-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00268-014-2484-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00268-014-2484-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00268-014-2484-4'


 

This table displays all metadata directly associated to this object as RDF triples.

374 TRIPLES      21 PREDICATES      140 URIs      126 LITERALS      36 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00268-014-2484-4 schema:about N02d07aae7f74460f96ba4a1ff8aeec4e
2 N046e1f697b6146cd82998162ec0a73b7
3 N0848dba2effb47afa6ef848e6296ad37
4 N0870050af0c146ca99b7ee0c5d3be0d4
5 N103ebc8f578341c3876ffa95ca03844d
6 N1f762f3d1fbb40ce860efc56a49f4b8b
7 N2b41c4842d1f41a784161a3aea273349
8 N398cc467eb304313847ce60f7d955211
9 N4a8c876d6d494c4e8817d2ce22add573
10 N5162dd67811849479acdef567c1d7e40
11 N551fceff15514093a3890f5f74637a16
12 N66c299d04d8d4696931dd7e2e37ce6d7
13 N81304c20c73a497cafb39be1d9a5ddcc
14 N847cf0c8f5014e55b8222f62561a3156
15 Nbaabae649027467bb9506f56f2ad98f4
16 Nc12787b951664b6fbbdadd849159ea6b
17 Nc19041c515fa468ea8eee3dd32bfecf8
18 Nc7711b24678249a6bffa31957805a3fa
19 Nd236e4464299420b8bc78d16886593ec
20 Nd6122136deaa497aa655f315f13de7c1
21 Nd9642d5da5184e558bb8461f7d03e03c
22 Ne0eaa41377d343779e002c25461c062f
23 Ne5c555318c6d4583b8845cbd437cc7d9
24 Ne96fbe7d153d4a04b40f72a48dd33c74
25 Nebe650e150b047b2873058adc5007d60
26 Ned3748a8f04a40728b6714551a0d16ed
27 Nf1105807764a490fac9b5445bbbc756d
28 Nf55cd1ac738e472fb24bacd77e1aecab
29 Nf8be19ffccf44069b13d6a1703d22956
30 anzsrc-for:11
31 anzsrc-for:1103
32 anzsrc-for:1112
33 schema:author N24cab92f827840deb677560e0bdaea39
34 schema:citation sg:pub.10.1245/s10434-009-0409-5
35 sg:pub.10.1245/s10434-009-0413-9
36 sg:pub.10.1245/s10434-009-0416-6
37 sg:pub.10.1245/s10434-009-0716-x
38 sg:pub.10.1245/s10434-012-2358-7
39 schema:datePublished 2014-03-11
40 schema:datePublishedReg 2014-03-11
41 schema:description BackgroundAdrenal cortical carcinoma (ACC) may have tumor or patient characteristics at presentation that argue against immediate surgery because of an unacceptable risk of morbidity/mortality, incomplete resection, or recurrence. This clinical stage can be characterized as borderline resectable ACC (BRACC). At present, systemic therapies in ACC can reduce tumor burden in some patients, creating an opportunity in BRACC for a strategy of preoperative chemotherapy (ctx) followed by surgery.Materials and MethodsA single-institution retrospective review was conducted of all patients considered for surgery for primary ACC. Patients with BRACC treated with preoperative ctx were categorized as follows: group A, imaging suggesting a need for multiorgan/vascular resection; group B, imaging suggesting potentially resectable oligometastases; and group C, patients having marginal performance status/comorbidities precluding immediate surgery. Both the disease-free survival (DFS) and the overall survival (OS) were compared in BRACC patients treated with preoperative ctx+surgery and those who had upfront surgery.ResultsFifty-three patients with primary ACC were considered for surgery (median follow-up: 49.9 months). Thirty-eight patients (71.7 %) had initial surgery and 15 of them (28.3 %) were considered BRACC and received preoperative therapy. Of these 15 patients, 12 (80 %) received combination therapy with mitotane and etoposide/cisplatin-based ctx, 2 (13 %) received mitotane alone, and 1 (7 %) received ctx alone. Six patients were defined as group A, 5 as group B, and 4 as group C. Thirteen (87 %) BRACC patients underwent surgical resection. BRACC patients were younger but had more advanced disease than the patients having initial surgery (stage IV in 40 vs 2.6 % [p < 0.01]). By Response Evaluation Criteria In Solid Tumors criteria, 5 patients (38.5 %) had a partial response, 7 (53.8 %) had stable disease, and 1 (7.7 %) had disease that progressed. Postoperative mitotane use was similar between groups (p = .15). Median DFS for resected BRACC patients was 28.0 months [95 % confidence interval (CI), 2.9–not attained] vs 13 months (95 % CI, 5.8–46.9) (p = 0.40) for initial surgery patients. Five-year OS rates were also similar: 65 % for resected BRACC vs 50 % for initial surgery (p = 0.72).ConclusionsThe favorable outcome of patients with BRACC, despite more advanced stage of disease compared to those treated with surgery first, together with uncommon disease progression, suggests a benefit of neoadjuvant treatment sequencing in patients with BRACC.
42 schema:genre article
43 schema:isAccessibleForFree false
44 schema:isPartOf N1ee91aaee76c492b92770c47700de391
45 N58fae836f2ed4360905bcf6b0d798e8e
46 sg:journal.1086446
47 schema:keywords ACC
48 CTX
49 Five-year OS rates
50 OS rates
51 Response Evaluation Criteria
52 ResultsFifty-three patients
53 Solid Tumors criteria
54 Tumors criteria
55 advanced disease
56 advanced stage
57 benefits
58 burden
59 carcinoma
60 characteristics
61 chemotherapy
62 clinical stage
63 combination therapy
64 comorbidities
65 cortical carcinoma
66 criteria
67 disease
68 disease progression
69 disease-free survival
70 evaluation criteria
71 favorable outcome
72 group
73 group A
74 group B
75 group C
76 immediate surgery
77 incomplete resection
78 initial surgery
79 materials
80 median disease-free survival
81 mitotane
82 months
83 morbidity/mortality
84 mortality
85 need
86 neoadjuvant treatment sequencing
87 oligometastases
88 opportunities
89 outcomes
90 overall survival
91 partial response
92 patient characteristics
93 patients
94 potential role
95 preoperative CTx
96 preoperative chemotherapy
97 preoperative therapy
98 presentation
99 primary ACC
100 progression
101 rate
102 recurrence
103 resection
104 response
105 retrospective review
106 review
107 risk
108 role
109 sequencing
110 single-institution retrospective review
111 stable disease
112 stage
113 strategies
114 surgery
115 surgery patients
116 surgical resection
117 survival
118 systemic therapy
119 therapy
120 treatment sequencing
121 tumor burden
122 tumors
123 unacceptable risk
124 upfront surgery
125 use
126 vascular resection
127 schema:name Borderline Resectable Adrenal Cortical Carcinoma: A Potential Role for Preoperative Chemotherapy
128 schema:pagination 1318-1327
129 schema:productId N450b79ba8510480cb8f2d542948567c7
130 Ncffb1bb28d93477eb2073faf8f281194
131 Nfdca58e581c94103ba627aad4f69702b
132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052270792
133 https://doi.org/10.1007/s00268-014-2484-4
134 schema:sdDatePublished 2022-09-02T15:57
135 schema:sdLicense https://scigraph.springernature.com/explorer/license/
136 schema:sdPublisher Nbe17de5f436a41d79a324410c84abab0
137 schema:url https://doi.org/10.1007/s00268-014-2484-4
138 sgo:license sg:explorer/license/
139 sgo:sdDataset articles
140 rdf:type schema:ScholarlyArticle
141 N02d07aae7f74460f96ba4a1ff8aeec4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Aged
143 rdf:type schema:DefinedTerm
144 N046e1f697b6146cd82998162ec0a73b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Antineoplastic Combined Chemotherapy Protocols
146 rdf:type schema:DefinedTerm
147 N0764e6afa06d4f09a2de8ff5508caa80 rdf:first sg:person.015020157564.00
148 rdf:rest N89042b0eb3d345209a0a4a8e90d85339
149 N0848dba2effb47afa6ef848e6296ad37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Humans
151 rdf:type schema:DefinedTerm
152 N0870050af0c146ca99b7ee0c5d3be0d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Neoadjuvant Therapy
154 rdf:type schema:DefinedTerm
155 N0b5263bbb5d74a02b6cbc748e0b04b80 rdf:first sg:person.01123234424.18
156 rdf:rest Nc70b6393d13a47a08ebae7a0f7a05fc0
157 N103ebc8f578341c3876ffa95ca03844d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Middle Aged
159 rdf:type schema:DefinedTerm
160 N16bc2a40a14f47fe867eec5e181b7472 rdf:first sg:person.010520141322.32
161 rdf:rest Nc1c5abf6cadb4c858db524bd12cd883a
162 N1ee91aaee76c492b92770c47700de391 schema:issueNumber 6
163 rdf:type schema:PublicationIssue
164 N1f762f3d1fbb40ce860efc56a49f4b8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Neoplasm Staging
166 rdf:type schema:DefinedTerm
167 N2229610dd7294d0ebf24790a36e6867b rdf:first sg:person.01040121722.56
168 rdf:rest N0b5263bbb5d74a02b6cbc748e0b04b80
169 N24cab92f827840deb677560e0bdaea39 rdf:first sg:person.0641505371.98
170 rdf:rest N44935c48dab248318eade260e749a657
171 N2b41c4842d1f41a784161a3aea273349 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Treatment Outcome
173 rdf:type schema:DefinedTerm
174 N398cc467eb304313847ce60f7d955211 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Female
176 rdf:type schema:DefinedTerm
177 N44935c48dab248318eade260e749a657 rdf:first sg:person.014015460707.20
178 rdf:rest Nd019dafa6507455abebc84416226c0b1
179 N450b79ba8510480cb8f2d542948567c7 schema:name pubmed_id
180 schema:value 24615603
181 rdf:type schema:PropertyValue
182 N4a8c876d6d494c4e8817d2ce22add573 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Disease-Free Survival
184 rdf:type schema:DefinedTerm
185 N5162dd67811849479acdef567c1d7e40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Follow-Up Studies
187 rdf:type schema:DefinedTerm
188 N551fceff15514093a3890f5f74637a16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Preoperative Care
190 rdf:type schema:DefinedTerm
191 N58fae836f2ed4360905bcf6b0d798e8e schema:volumeNumber 38
192 rdf:type schema:PublicationVolume
193 N66c299d04d8d4696931dd7e2e37ce6d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Cohort Studies
195 rdf:type schema:DefinedTerm
196 N81304c20c73a497cafb39be1d9a5ddcc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Immunohistochemistry
198 rdf:type schema:DefinedTerm
199 N847cf0c8f5014e55b8222f62561a3156 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Neoplasm Invasiveness
201 rdf:type schema:DefinedTerm
202 N89042b0eb3d345209a0a4a8e90d85339 rdf:first sg:person.01331416616.43
203 rdf:rest rdf:nil
204 Nbaabae649027467bb9506f56f2ad98f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Aged, 80 and over
206 rdf:type schema:DefinedTerm
207 Nbe17de5f436a41d79a324410c84abab0 schema:name Springer Nature - SN SciGraph project
208 rdf:type schema:Organization
209 Nc12787b951664b6fbbdadd849159ea6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Survival Analysis
211 rdf:type schema:DefinedTerm
212 Nc19041c515fa468ea8eee3dd32bfecf8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Time Factors
214 rdf:type schema:DefinedTerm
215 Nc1c5abf6cadb4c858db524bd12cd883a rdf:first sg:person.010313117317.85
216 rdf:rest Ndc7f917cc5fe4e8d9ede65801632a84e
217 Nc705060d6aa746e0bb2ace36c52f329d rdf:first sg:person.01331214305.47
218 rdf:rest N2229610dd7294d0ebf24790a36e6867b
219 Nc70b6393d13a47a08ebae7a0f7a05fc0 rdf:first sg:person.011430047362.24
220 rdf:rest N16bc2a40a14f47fe867eec5e181b7472
221 Nc7711b24678249a6bffa31957805a3fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Role
223 rdf:type schema:DefinedTerm
224 Ncffb1bb28d93477eb2073faf8f281194 schema:name dimensions_id
225 schema:value pub.1052270792
226 rdf:type schema:PropertyValue
227 Nd019dafa6507455abebc84416226c0b1 rdf:first sg:person.07703274637.33
228 rdf:rest Nc705060d6aa746e0bb2ace36c52f329d
229 Nd236e4464299420b8bc78d16886593ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
230 schema:name Retrospective Studies
231 rdf:type schema:DefinedTerm
232 Nd6122136deaa497aa655f315f13de7c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
233 schema:name Biopsy, Needle
234 rdf:type schema:DefinedTerm
235 Nd9642d5da5184e558bb8461f7d03e03c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
236 schema:name Adrenalectomy
237 rdf:type schema:DefinedTerm
238 Ndc7f917cc5fe4e8d9ede65801632a84e rdf:first sg:person.0630717166.06
239 rdf:rest N0764e6afa06d4f09a2de8ff5508caa80
240 Ne0eaa41377d343779e002c25461c062f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
241 schema:name Adult
242 rdf:type schema:DefinedTerm
243 Ne5c555318c6d4583b8845cbd437cc7d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
244 schema:name Young Adult
245 rdf:type schema:DefinedTerm
246 Ne96fbe7d153d4a04b40f72a48dd33c74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
247 schema:name Male
248 rdf:type schema:DefinedTerm
249 Nebe650e150b047b2873058adc5007d60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
250 schema:name Adrenal Cortex Neoplasms
251 rdf:type schema:DefinedTerm
252 Ned3748a8f04a40728b6714551a0d16ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
253 schema:name Tomography, X-Ray Computed
254 rdf:type schema:DefinedTerm
255 Nf1105807764a490fac9b5445bbbc756d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
256 schema:name Adrenocortical Carcinoma
257 rdf:type schema:DefinedTerm
258 Nf55cd1ac738e472fb24bacd77e1aecab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
259 schema:name Confidence Intervals
260 rdf:type schema:DefinedTerm
261 Nf8be19ffccf44069b13d6a1703d22956 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
262 schema:name Statistics, Nonparametric
263 rdf:type schema:DefinedTerm
264 Nfdca58e581c94103ba627aad4f69702b schema:name doi
265 schema:value 10.1007/s00268-014-2484-4
266 rdf:type schema:PropertyValue
267 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
268 schema:name Medical and Health Sciences
269 rdf:type schema:DefinedTerm
270 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
271 schema:name Clinical Sciences
272 rdf:type schema:DefinedTerm
273 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
274 schema:name Oncology and Carcinogenesis
275 rdf:type schema:DefinedTerm
276 sg:grant.2438826 http://pending.schema.org/fundedItem sg:pub.10.1007/s00268-014-2484-4
277 rdf:type schema:MonetaryGrant
278 sg:journal.1086446 schema:issn 0364-2313
279 1432-2323
280 schema:name World Journal of Surgery
281 schema:publisher Springer Nature
282 rdf:type schema:Periodical
283 sg:person.010313117317.85 schema:affiliation grid-institutes:grid.240145.6
284 schema:familyName Ng
285 schema:givenName Chaan S.
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010313117317.85
287 rdf:type schema:Person
288 sg:person.01040121722.56 schema:affiliation grid-institutes:grid.240145.6
289 schema:familyName Wood
290 schema:givenName Christopher
291 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56
292 rdf:type schema:Person
293 sg:person.010520141322.32 schema:affiliation grid-institutes:grid.240145.6
294 schema:familyName Katz
295 schema:givenName Matthew H.
296 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010520141322.32
297 rdf:type schema:Person
298 sg:person.01123234424.18 schema:affiliation grid-institutes:grid.240145.6
299 schema:familyName Vauthey
300 schema:givenName Nicholas
301 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123234424.18
302 rdf:type schema:Person
303 sg:person.011430047362.24 schema:affiliation grid-institutes:grid.30760.32
304 schema:familyName Evans
305 schema:givenName Douglas B.
306 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011430047362.24
307 rdf:type schema:Person
308 sg:person.01331214305.47 schema:affiliation grid-institutes:grid.240145.6
309 schema:familyName Milton
310 schema:givenName Denai R.
311 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331214305.47
312 rdf:type schema:Person
313 sg:person.01331416616.43 schema:affiliation grid-institutes:grid.240145.6
314 schema:familyName Grubbs
315 schema:givenName Elizabeth G.
316 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331416616.43
317 rdf:type schema:Person
318 sg:person.014015460707.20 schema:affiliation grid-institutes:grid.240145.6
319 schema:familyName Habra
320 schema:givenName Mouhammed Amir
321 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014015460707.20
322 rdf:type schema:Person
323 sg:person.015020157564.00 schema:affiliation grid-institutes:grid.240145.6
324 schema:familyName Lee
325 schema:givenName Jeffrey E.
326 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015020157564.00
327 rdf:type schema:Person
328 sg:person.0630717166.06 schema:affiliation grid-institutes:grid.240145.6
329 schema:familyName Perrier
330 schema:givenName Nancy D.
331 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630717166.06
332 rdf:type schema:Person
333 sg:person.0641505371.98 schema:affiliation grid-institutes:grid.240145.6
334 schema:familyName Bednarski
335 schema:givenName Brian K.
336 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0641505371.98
337 rdf:type schema:Person
338 sg:person.07703274637.33 schema:affiliation grid-institutes:None
339 schema:familyName Phan
340 schema:givenName Alexandria
341 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07703274637.33
342 rdf:type schema:Person
343 sg:pub.10.1245/s10434-009-0409-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033782523
344 https://doi.org/10.1245/s10434-009-0409-5
345 rdf:type schema:CreativeWork
346 sg:pub.10.1245/s10434-009-0413-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018660030
347 https://doi.org/10.1245/s10434-009-0413-9
348 rdf:type schema:CreativeWork
349 sg:pub.10.1245/s10434-009-0416-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036571674
350 https://doi.org/10.1245/s10434-009-0416-6
351 rdf:type schema:CreativeWork
352 sg:pub.10.1245/s10434-009-0716-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1009990166
353 https://doi.org/10.1245/s10434-009-0716-x
354 rdf:type schema:CreativeWork
355 sg:pub.10.1245/s10434-012-2358-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029414516
356 https://doi.org/10.1245/s10434-012-2358-7
357 rdf:type schema:CreativeWork
358 grid-institutes:None schema:alternateName Department of Medical Oncology, Methodist Cancer Center, 77030, Houston, TX, USA
359 schema:name Department of Medical Oncology, Methodist Cancer Center, 77030, Houston, TX, USA
360 rdf:type schema:Organization
361 grid-institutes:grid.240145.6 schema:alternateName Department of Biostatistics, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA
362 Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA
363 Department of Radiology, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA
364 Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA
365 Department of Urology, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA
366 schema:name Department of Biostatistics, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA
367 Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA
368 Department of Radiology, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA
369 Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, 77030, Houston, TX, USA
370 Department of Urology, University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA
371 rdf:type schema:Organization
372 grid-institutes:grid.30760.32 schema:alternateName Department of Surgery, Medical College of Wisconsin, 53226, Milwaukee, WI, USA
373 schema:name Department of Surgery, Medical College of Wisconsin, 53226, Milwaukee, WI, USA
374 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...